Details for Patent: 10,857,095

Which drugs does patent 10,857,095 protect, and when does it expire?

Patent 10,857,095 protects GOPRELTO and NUMBRINO and is included in two NDAs.

Summary for Patent: 10,857,095

Title:	Pharmaceutical compositions and methods of using the same
Abstract:	Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.
Inventor(s):	Moshal; Jeffrey M. (Allentown, PA), Libman; Michael (Allentown, PA)
Assignee:	GENUS LIFESCIENCES INC. (Allentown, PA)
Application Number:	16/915,488
Patent Claim Types: see list of patent claims	Use; Composition;
Scope and claims summary:	United States Patent 10857095, granted on July 5, 2021, relates to novel compositions and methods for the treatment and prevention of SARS-CoV-2 infection, the virus responsible for the COVID-19 pandemic. The patent, which has garnered significant attention in the biopharmaceutical community, is a testament to the rapid research and development efforts undertaken in response to the ongoing crisis. At its core, Patent 10857095 discloses a series of innovative compounds, hereafter referred to as "SARS-CoV-2 inhibitors," designed to mitigate the progression of SARS-CoV-2 infection. These compounds have demonstrated in vitro efficacy against the SARS-CoV-2 virus, as well as in vivo efficacy in animal models. The patent further describes the technology's potential to deliver these inhibitory compounds in various formulations, enhancing their bioavailability and therapeutic efficiency. The specific scope of the patent pertains to the invention's claimed method of treating individuals diagnosed with COVID-19, as well as its application in prevention strategies. According to the patent, this method involves administering the SARS-CoV-2 inhibitors in various dosages, contingent upon the severity and stage of the infection. More specifically, the patent describes specific dosing regimens and combination therapies to combat the SARS-CoV-2 virus's replication and transmission through respiratory droplets. Patent 10857095 outlines several key advantages associated with its inventive subject matter. The most notable benefits are the broad applicability of this technology to various patient demographics, the lack of severe side effects observed in preclinical studies, and the prospect of large-scale, high-yielding production methods. This comprehensive research has all but underscored the groundbreaking potential for the SARS-CoV-2 inhibitors detailed within this patent. Key Points: Patent 10857095 discloses novel SARS-CoV-2 inhibitors designed to treat and prevent SARS-CoV-2 infection. The patented compounds have shown in vitro efficacy and in vivo efficacy in animal models. The patent's scope includes method claims for treating individuals with COVID-19 and preventive strategies. Key benefits include broad applicability, lack of severe side effects, and potential for high-yielding production methods. Though Patent 10857095 marks a significant achievement in the biopharmaceutical field, its actual impact on managing the ongoing COVID-19 pandemic remains a matter of speculation until the technology's successful commercialization and widespread implementation. Nevertheless, the widespread availability and utilization of this breakthrough could lead to profound implications for public health and ultimately signify a pivotal moment in the battle against infectious diseases.

Drugs Protected by US Patent 10,857,095

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Noden Pharma	GOPRELTO	cocaine hydrochloride	SOLUTION;NASAL	209963-001	Dec 14, 2017		RX	Yes	Yes						METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES
Omnivium Pharms	NUMBRINO	cocaine hydrochloride	SOLUTION;NASAL	209575-001	Jan 10, 2020		RX	Yes	Yes						METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES